Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT07451522

Comparative Analysis of Analgesic Approaches in the Early Period After CABG

Led by Primorsky Regional General Hospital #1 · Updated on 2026-03-05

100

Participants Needed

1

Research Sites

14 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to study postoperative analgesia in patients undergoing CABG. And learn if tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) treats pain not inferiory then morphine. The main questions it aims to answer are: Does tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) lower the VAS score same way as a morphine? What medical problems do participants have when taking tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid)? Participants will: Group (1)- subcutaneous single dose of morphine 10 mg would be administred based on VAS score \> 3 during 24 hours after CABG. Exprimental group (2)- subcutaneous single dose of tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) - 0.4 mg would be administred based on VAS score \> 3 during 24 hours after CABG. Efficacy was assessed using the VAS scale decreassion. Hemodynamic parameters and arterial blood gases were also assessed.

CONDITIONS

Official Title

Comparative Analysis of Analgesic Approaches in the Early Period After CABG

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • ASA score less than 3
  • Signed informed consent
  • No preoperative drugs affecting pain perception
  • No active infection process
  • Body mass index between 18.5 and 35 kg/m2
  • Undergoing coronary artery bypass grafting (CABG)
  • Age between 18 and 75 years
Not Eligible

You will not qualify if you...

  • Does not meet inclusion criteria
  • ASA class IV or higher indicating high severity
  • Contraindications to tafalgin or morphine, including hypersensitivity
  • Pregnancy or lactation
  • Acute or chronic intoxication with substances depressing the central nervous system
  • Use of monoamine oxidase inhibitors (MAOIs) or less than 14 days since stopping them
  • Liver cirrhosis, Child-Pugh class C
  • Acute renal failure requiring renal replacement therapy
  • Unresected malignant tumor
  • Mesenteric thrombosis or severe unexplained abdominal pain
  • Participation in another clinical study
  • Severe central nervous system depression (except acute poisoning)
  • COPD stage III or bronchial asthma in exacerbation
  • Any significant medical condition that prevents study participation
  • Psychiatric or physical conditions preventing proper assessment or compliance
  • Postoperative hemodynamic instability requiring high-dose inotropic or vasopressor support or mechanical circulatory support
  • Refusal to participate in the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Primorsky Regional General Hospital #1

Vladivostok, Outside US, Russia, 690091

Actively Recruiting

Loading map...

Research Team

V

Vladislav Rublev, PhD

CONTACT

E

Evgenii Kokarev, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Comparative Analysis of Analgesic Approaches in the Early Period After CABG | DecenTrialz